未登录 分享 收藏
分享 收藏
Applying Computational Protein Design to Engineer Affibodies for Affinity-controlled Delivery of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor 应用计算蛋白质设计技术工程化改造Affibodies，以实现对血管内皮生长因子和血小板衍生生长因子的亲和力控制递送 Svendsen, Justin E.; Ford, Madeleine R.; Asnes, Chandler L.; Oh, Simon C.; Dorogin, Jonathan; Fear, Karly M.; O'Hara-Smith, Johnathan R.; Chisholm, Lauren O.; Phillips, Sophia R.; Harms, Michael J.; Hosseinzadeh, Parisa; Hettiaratchi, Marian H. 分享 收藏
分享 收藏
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial Nivolumab联合化疗治疗HER2-negative，既往未治疗，不可切除，晚期或复发性胃/胃食管交界癌患者: 吸引-4随机，双盲，安慰剂对照，3期临床试验的3年随访 Boku, Narikazu; Omori, Takeshi; Shitara, Kohei; Sakuramoto, Shinichi; Yamaguchi, Kensei; Kato, Ken; Kadowaki, Shigenori; Tsuji, Kunihiro; Ryu, Min-Hee; Oh, Do-Youn; Oh, Sang Cheul; Rha, Sun Young; Lee, Keun-Wook; Chung, Ik-Joo; Sym, Sun Jin; Chen, Li-Tzong; Chen, Jen-Shi; Bai, Li-Yuan; Nakada, Takashi; Hagihara, Shunsuke; Makino, Reina; Nishiyama, Eiji; Kang, Yoon-Koo 分享 收藏
Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis 贝马妥珠单抗联合mFOLFOX6作为东亚FGFR2b-overexpressing局部晚期或转移性胃/胃食管交界癌患者的一线治疗: FIGHT最终分析亚组 Kang, Yoon-Koo; Qin, Shukui; Lee, Keun-Wook; Oh, Sang Cheul; Kim, In-Ho; Kim, Jong Gwang; Li, Yong; Yan, Zhuchen; Li, Jin; Bai, Li-Yuan; Chan, Catherine; Yusuf, Akeem; Zahlten-Kuemeli, Anita; Taylor, Kate; Yamaguchi, Kensei 分享 收藏
Analysis of the effect of FGFR inhibitor and cannabidiol in colorectal cancer Ju, Yeonuk; Kim, Wooyoung; Kim, Bugyeom; Kim, Jiyoung; Bong, Junwoo; Cheong, Chinock; Kang, Sanghee; Min, Byung Wook; Oh, Sang Cheul; Lee, Sun Il 分享 收藏
分享 收藏
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial Bemarituzumab作为局部晚期或转移性胃/胃食管交界处腺癌的一线治疗: 随机2期临床试验的最终分析 Wainberg, Zev A.; Kang, Yoon-Koo; Lee, Keun-Wook; Qin, Shukui; Yamaguchi, Kensei; Kim, In-Ho; Saeed, Anwaar; Oh, Sang Cheul; Li, Jin; Turk, Haci Mehmet; Teixeira, Alexandra; Hitre, Erika; Udrea, Adrian A.; Cardellino, Giovanni Gerardo; Sanchez, Raquel Guardeno; Zahlten-Kuemeli, Anita; Taylor, Kate; Enzinger, Peter C. 分享 收藏
Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 Finn, R. S.; Ueno, M.; Yoo, C.; Ren, Z.; Furuse, J.; Kelley, R. K.; Chan, S. L.; Edeline, J.; Klumpen, H. J.; Yau, T.; Oh, S. C.; Ozaka, M.; Kim, J. G.; Park, J. O.; Vogel, A.; Valle, J. W.; Yu, L.; Malhotra, U.; Siegel, A. B.; Qin, S. 分享 收藏
Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma Lordick, F.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Bang, Y-J.; Enzinger, P. C.; Ilson, D. H.; van Cutsem, E.; Gallego Plazas, J.; Huang, J.; Shen, L.; Oh, S. C.; Sunpaweravong, P.; Soo, H. H. F.; Turk, H. M.; Park, J. W.; Moran, D.; Bhattacharya, P.; Cao, Y. J.; Xu, R-H. 分享 收藏
Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis Kang, Y-K.; Qin, S.; Lee, K-W.; Oh, S. C.; Kim, I-H.; Kim, J. G.; Li, Y.; Yan, Z.; Li, J.; Bai, L-Y.; Chan, C. P. K.; Yusuf, A.; Zahlten-Kuemeli, A.; Taylor, K.; Yamaguchi, K. 分享 收藏
Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study Lee, K-W.; Bai, L-Y.; Jung, M.; Ying, J.; Im, Y-H.; Oh, D-Y.; Cho, J. Y.; Oh, S. C.; Chao, Y.; Zhou, P.; Bao, Y.; Kang, Y-K. 分享 收藏
Discrepancies between psychological stress and emotional care in cancer patients revealed in a social listening analysis 社交听力分析显示癌症患者心理压力与情绪护理之间的差异 Kim, D.; Lim, J. H.; Kim, I-H.; Park, S. E.; Kim, I.; Jo, J.; Byun, J. H.; Oh, S. C.; Lee, H. W.; Lee, S-C. 分享 收藏
Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised phase III TOPAZ-1 study He, A. R.; Bouattour, M.; Gupta, V. G.; Evesque, L.; Zhen, D. B.; Park, J. O.; Sookprasert, A.; Salvatierra, A.; Vaccaro, G. M.; Oh, S. C.; Ostoich, S. A.; Satoh, T.; Zotkiewicz, M.; Rokutanda, N.; Kim, H.; Oh, D-Y. 分享 收藏
Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma Lordick, F.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Bang, Y-J.; Enzinger, P. C.; Ilson, D. H.; Van Cutsem, E.; Plazas, J. Gallego; Huang, J.; Shen, L.; Oh, S. C.; Sunpaweravong, P.; Soo, H. H. F.; Turk, H. M.; Park, J. W.; Moran, D.; Bhattacharya, P.; Cao, Y. J.; Xu, R-H. 分享 收藏
Clinically conserved genomic subtypes of gastric adenocarcinoma Jeong, Yun Seong; Eun, Young-Gyu; Lee, Sung Hwan; Kang, Sang-Hee; Yim, Sun Young; Kim, Eui Hyun; Noh, Joo Kyung; Sohn, Bo Hwa; Woo, Seon Rang; Kong, Moonkyoo; Nam, Deok Hwa; Jang, Hee-Jin; Lee, Hyun-Sung; Song, Shumei; Oh, Sang Cheul; Lee, Jeeyun; Ajani, Jaffer A.; Lee, Ju-Seog 分享 收藏
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial Zolbetuximab联合CAPOX治疗CLDN18.2阳性胃或胃食管交界处腺癌: 随机，3期GLOW试验 Shah, Manish A.; Shitara, Kohei; Ajani, Jaffer A.; Bang, Yung-Jue; Enzinger, Peter; Ilson, David; Lordick, Florian; Van Cutsem, Eric; Plazas, Javier Gallego; Huang, Jing; Shen, Lin; Oh, Sang Cheul; Sunpaweravong, Patrapim; Soo Hoo, Hwoei Fen; Turk, Haci Mehmet; Oh, Mok; Park, Jung Wook; Moran, Diarmuid; Bhattacharya, Pranob; Arozullah, Ahsan; Xu, Rui-Hua 分享 收藏
Bemarituzumab for treatment of previously untreated advanced and/or metastatic gastric and gastroesophageal cancer (GC): Final analysis of a randomized phase 2 trial (FIGHT) Wainberg, Z.; Kang, Y.; Lee, K.; Qin, S.; Yamaguchi, K.; Kim, I.; Saeed, A.; Oh, S.; Li, J.; Turk, H.; Teixeira, A.; Hitre, E.; Udrea, A.; Cardellino, G.; Guardeno Sanchez, R.; Zahlten-Kumeli, A.; Taylor, K.; Enzinger, P. 分享 收藏
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial Napabucasin联合nab-紫杉醇联合吉西他滨与nab-紫杉醇联合吉西他滨在先前未治疗的转移性胰腺癌中的比较: 一项适应性多中心，随机，开放标签，3期，优越性试验 Bekaii-Saab, Tanios; Okusaka, Takuji; Goldstein, David; Oh, Do-Youn; Ueno, Makoto; Ioka, Tatsuya; Fang, Weijia; Anderson, Eric C.; Noel, Marcus S.; Reni, Michele; Choi, Hye Jin; Goldberg, Jonathan S.; Oh, Sang Cheul; Li, Chung-Pin; Tabernero, Josep; Li, Jian; Foos, Emma; Oh, Cindy; Van Cutsem, Eric 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
GASTRIC CANCER.png)
OAAI
.png){kind=icon}
分享.png){kind=icon}
收藏